Michael Bengtson, MD

College Of Medicine Psychiatry And Behavioral Neurosciences

Academic Email: mbengtso@health.usf.edu

Academic Phone: (813) 974-5926

Education

  • MD, Medicine, University Of Alabama - School Of Medicine, 1989

Interdisciplinary and Emerging Signature Programs

  • Neuroscience

Recent Publications

  • Ried LD, Brumback B, Bengtson MA, Garman PM, Hsu C, McConkey JR. Glucose dysregulation among veterans living with schizophrenia-related disorders after switching second-generation antipsychotics. Journal of the American Pharmacists Association : JAPhA. 49(2) : 223-31http://www.ncbi.nlm.nih.gov/pubmed/19289350
  • Hsu C, Ried LD, Bengtson MA, Garman PM, McConkey JR, Rahnavard F. Metabolic monitoring in veterans with schizophrenia-related disorders and treated with second-generation antipsychotics: findings from a Veterans Affairs-based population. Journal of the American Pharmacists Association : JAPhA. 48(3) : 393-400http://www.ncbi.nlm.nih.gov/pubmed/18595825
  • Storch EA, Murphy TK, Goodman WK, Geffken GR, Lewin AB, Henin A, Micco JA, Sprich S, Wilhelm S, Bengtson M, Geller DA. A preliminary study of D-cycloserine augmentation of cognitive-behavioral therapy in pediatric obsessive-compulsive disorder. Biological psychiatry. 68(11) : 1073-6, 2010. http://www.ncbi.nlm.nih.gov/pubmed/20817153
  • Murphy TK, Mutch PJ, Reid JM, Edge PJ, Storch EA, Bengtson M, Yang M. Open label aripiprazole in the treatment of youth with tic disorders. Journal of child and adolescent psychopharmacology. 19(4) : 441-7, 2009. http://www.ncbi.nlm.nih.gov/pubmed/19702496
  • Leonard CM, Kuldau JM, Maron L, Ricciuti N, Mahoney B, Bengtson M, DeBose C. Identical neural risk factors predict cognitive deficit in dyslexia and schizophrenia. Neuropsychology. 22(2) : 147-58, 2008. http://www.ncbi.nlm.nih.gov/pubmed/18331156
  • Storch EA, Merlo LJ, Bengtson M, Murphy TK, Lewis MH, Yang MC, Jacob ML, Larson M, Hirsh A, Fernandez M, Geffken GR, Goodman WK. D-cycloserine does not enhance exposure-response prevention therapy in obsessive-compulsive disorder. International clinical psychopharmacology. 22(4) : 230-7, 2007. http://www.ncbi.nlm.nih.gov/pubmed/17519647